CONTEXT: Epidemiological, clinical and familial studies indicate that anxiety disorders (ADs) are highly comorbid in persons with bipolar disorder (BPD). The phenomenological overlap between ADs and BPD is reported more frequently in individuals with female predominant bipolar presentations (e.g., bipolar II disorder). Anxiety comorbidity in the BPD population poses a serious hazard. For example, it is associated with an intensification of symptoms, non-recovery, substance use comorbidity and harmful dysfunction (e.g., suicidality). OBJECTIVE: The evidentiary base informing treatment decisions for the anxious bipolar patient is woefully inadequate. Several expert consensus and evidence-based treatment guidelines for BPD suggest various treatment avenues, although these have been insufficiently studied. The encompassing aim of this paper is to synthesize extant studies reporting on the co-occurrence of AD and BPD. Taken together, a compelling basis emerges for prioritizing the identification and management of anxiety symptomatology in the BPD population.
CONTEXT: Epidemiological, clinical and familial studies indicate that anxiety disorders (ADs) are highly comorbid in persons with bipolar disorder (BPD). The phenomenological overlap between ADs and BPD is reported more frequently in individuals with female predominant bipolar presentations (e.g., bipolar II disorder). Anxiety comorbidity in the BPD population poses a serious hazard. For example, it is associated with an intensification of symptoms, non-recovery, substance use comorbidity and harmful dysfunction (e.g., suicidality). OBJECTIVE: The evidentiary base informing treatment decisions for the anxious bipolarpatient is woefully inadequate. Several expert consensus and evidence-based treatment guidelines for BPD suggest various treatment avenues, although these have been insufficiently studied. The encompassing aim of this paper is to synthesize extant studies reporting on the co-occurrence of AD and BPD. Taken together, a compelling basis emerges for prioritizing the identification and management of anxiety symptomatology in the BPD population.
Authors: Madison K Titone; Rachel D Freed; Jared K O'Garro-Moore; Andrew Gepty; Tommy H Ng; Jonathan P Stange; Lyn Y Abramson; Lauren B Alloy Journal: Psychiatry Res Date: 2018-04-03 Impact factor: 3.222
Authors: Keming Gao; Philip K Chan; Marcia L Verduin; David E Kemp; Bryan K Tolliver; Stephen J Ganocy; Sarah Bilali; Kathleen T Brady; Robert L Findling; Joseph R Calabrese Journal: Am J Addict Date: 2010 Sep-Oct
Authors: Keming Gao; Bryan K Tolliver; David E Kemp; Stephen J Ganocy; Sarah Bilali; Kathleen L Brady; Robert L Findling; Joseph R Calabrese Journal: J Clin Psychiatry Date: 2009-07 Impact factor: 4.384
Authors: Steven Jones; Elly McGrath; Kay Hampshire; Rebecca Owen; Lisa Riste; Chris Roberts; Linda Davies; Debbie Mayes Journal: BMC Psychiatry Date: 2013-02-15 Impact factor: 3.630
Authors: Janaina Mourão-Miranda; Leticia Oliveira; Cecile D Ladouceur; Andre Marquand; Michael Brammer; Boris Birmaher; David Axelson; Mary L Phillips Journal: PLoS One Date: 2012-02-15 Impact factor: 3.240
Authors: G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young Journal: J Psychopharmacol Date: 2016-03-15 Impact factor: 4.153